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O2 deprivation (hypoxia) and cellular proliferation engage opposite cellular pathways, yet often 
coexist during tumor growth. The ability of cells to grow during hypoxia results in part from crosstalk 
between hypoxia-inducible factors (HIFs) and the proto-oncogene c-Myc. Acting alone, HIF and 
c-Myc partially regulate complex adaptations undertaken by tumor cells growing in low O2. However, 
acting in concert these transcription factors reprogram metabolism, protein synthesis, and cell cycle 
progression, to “fine tune” adaptive responses to hypoxic environments.Tumor signaling pathways regulating energy production 
and macromolecular  synthesis  have  recently  garnered 




factor  or  nutrient  deprivation)  redirect  intermediate 
metabolites, sustaining bioenergetics and cell survival. 
Recent  studies  describe  crosstalk  between  the  c-Myc 
and HIF pathways, demonstrating an interplay between 
responses  to  oxygen  (O2)  deprivation  and  a  key  tran-
scription  factor  regulating growth  (Gordan et al., 2007; 
Koshiji  et  al.,  2004; Zhang et  al.,  2007).  In  this  review, 
we summarize the effects of c-Myc and HIFs on carbon 








amplification  and  translocation  gives  rise  to  extremely 
high protein levels, its upregulation more typically results 
from  altered  signal  transduction  and  is  therefore  more 
modest  (Nilsson  and  Cleveland,  2003).  c-Myc  acts  as 
both a transcriptional activator and repressor, promoting 
transcription (e.g., cyclin D2 and ornithine decarboxylase 
[ODC]) by binding E boxes (CACGTG) in a complex with 
Max, while inhibiting the expression of other genes (e.g., 





ily  members  L-Myc  and  N-Myc  have  also  been  identi-
fied. They regulate overlapping targets but have not been 
assessed for modulation by the HIFs and will not be dis-
cussed here (Adhikary and Eilers, 2005).108  Cancer Cell 12, August 2007 ©2007 Elsevier Inc.During  rapid  cellular  proliferation,  tumors  outstrip 
their  blood  supply,  limiting  O2  and  nutrient  availabil-
ity.  HIF-α  subunits  are  continuously  transcribed  and 
translated, but degraded under normoxia due  to pro-
lyl  hydroxylase  activity, marking  them  for  recognition 
by  the  von  Hippel-Lindau  (VHL)  tumor  suppressor 
ubiquitin  ligase  complex  and  proteasomal  degrada-
tion. Under hypoxia (typically below 3%–5% O2), HIF-
α  subunits  are  stabilized,  translocate  to  the  nucleus, 
dimerize with the stable β-subunit ARNT, and promote 
O2-regulated gene expression. HIF-1α and HIF-2α, the 
best  characterized  HIF-α  subunits,  are  differentially 
expressed: HIF-1α  is ubiquitously expressed and HIF-
2α is restricted to endothelial, lung, renal, and hepatic 
cells  (Wiesener  et  al.,  2003),  although  it  has  been 
observed in tumors of other tissues (Semenza, 2003). 
While HIF-1α and HIF-2α have shared targets, such as 
vascular endothelial growth factor (VEGF ) and adipose 










Growth  factors  induce  coordinated  transcriptional, 
translational,  and  posttranslational  changes  to  sup-
port cell cycle progression, increasing nutrient uptake 
and  glycolytic  metabolism.  The  resulting  elevation 
in  glucose  metabolism  occurs  despite  adequate  O2 
for  mitochondrial  oxidative  phosphorylation,  a  more 
efficient  form of ATP production  (Bauer et al., 2004). 
Pyruvate is produced at a higher rate than it is metab-
olized  by  mitochondria,  with  excesses  converted  to 
lactate by Lactate Dehydrogenase (LDH-A).
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green arrows showing promotion by both.In  transformed  cells,  high  levels  of  c-Myc  promote 
energy production and biomolecule synthesis  required 
for  rapid  proliferation,  independent  of  growth  factor 
stimulation.  c-Myc  enhances  the  glycolytic  pathway, 
increasing  target gene expression  from glucose  trans-
porters  through pyruvate kinase  (listed  in Figure 1),  as 
well  as LDH-A,  allowing efflux of  glucose-derived car-
bon as  lactate  (Osthus et al., 2000; Shim et al., 1997). 
Interestingly,  LDH-A  knockdown  has  been  shown  to 
inhibit  transformed  mammary  epithelial  cell  prolifera-
tion in vitro and in subcutaneous allografts, possibly by 
promoting mitochondrial respiration (Fantin et al., 2006). 
While  diverting  pyruvate  away  from  mitochondria,  c-
Myc increases mitochondrial mass through targets such 




genesis  and  shift  metabolism  toward  glycolysis?  c-
Myc drives anabolic pathways, with targets including 
carbomyl phosphate synthetase aspartate transcar-
bomylase and dihydroorotase  (CAD), serine hydroxy-
methyltransferase  (SHMT ),  fatty acid synthase (FAS), 
and  ODC,  promoting  nucleotide,  amino  acid,  fatty 
acid,  and  polyamine  synthesis  (Coller  et  al.,  2000; 
O’Connell  et  al.,  2003). Each process  requires mito-
chondrial  intermediates.  The  importance  of  mito-







2005). Therefore, while the enhanced glycolysis main-tains  ATP  levels,  growth  promotion  by  c-Myc  also 
requires  mitochondrial  activity  to  produce  biosyn-
thetic substrates.
HIF-1α/ARNT  dimers  also  potently  enhance  glyco-
lytic  metabolism  (Figure  1)  with  targets  from  glucose 
transporters  through LDH-A  (Hu et  al.,  2003).  In  con-
trast  to  c-Myc,  HIF  specifically  blocks  access  of  gly-
colytic  end  products  to  mitochondria.  This  effect  is 





cytochrome c  oxidase  (COX),  substituting COX4-2  for 
COX4-1 via transcriptional upregulation of COX4-2 and 
the LON protease (which degrades COX4-1; Fukuda et 
al.,  2007). This  results  in enhanced electron  transport 
chain  (ETC)  efficiency  under  hypoxia,  with  increased 
ATP  production  and  decreased ROS  generation.  HIF-






















Cell  division  requires  high  levels  of  protein  synthesis, 
effected by growth factor signaling pathway convergence 





tion of  cap-dependent  translation. Supporting  increased 
translation initiation (shown in Figure 2), c-Myc promotes 
ribosome and  tRNA biogenesis  through  induction of  the 
45S pre-rRNA, tRNAs, and the 5S rRNA, enhancing Pol-
I-dependent rRNA transcription through direct DNA bind-
ing, and associating with  the Pol  III component TFIIIB  to 











shown in blue.110  Cancer Cell 12, August 2007 ©2007 Elsevier Inc.Rather  than  regulating  the  expression  of  translation 
machinery  components,  O2  deprivation  results  in  HIF-
dependent and HIF-independent inhibition of translation 




ics  (Koritzinsky  et  al.,  2006).  Even mild  hypoxia  (1.5% 
O2)  triggers  eIF-2α  phosphorylation  and  4E-BP  and 
p70S6K  hypophosphorylation  (Arsham  et  al.,  2003;  Liu 
et al., 2006). eIF-2α phosphorylation, which blocks 43S 
preinitiation  complex  regeneration,  is mediated  by  the 
endoplasmic  reticulum  resident kinase PERK  indepen-
dent of HIF  (Koumenis et al., 2002). 4E-BP hypophos-
phorylation is downstream of mTORC1 inhibition result-

























interaction  with  its  transcription  cofactors,  disrupting 







et  al.,  2005;  To  et  al.,  2006).  The Per/Arnt/Sim  (PAS)-
B  domain  of HIF-1α mediates  its  interaction with  Sp1. 
Though highly conserved in HIF-2α, the phosphorylation 




upper panel),  and  increased c-Myc effects on  the cell 
cycle regulators Cyclin D2, E2F1, p21, and p27 (Gordan 
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on c-Myc Transcriptional Activity
When  HIF-1α  is  induced  (A),  it  acts  rapidly  to 
disrupt  c-Myc  complexes.  By  inducing  Mxi,  it 







Mxi  induction  inhibits  expression  of  other  c-
Myc-activated targets (e.g., CAD and ODC).et al., 2007). These growth-promoting effects of HIF-2α 
occur rapidly and are detected within 1–2 hr at 0.5% O2. 
Furthermore,  they are  likely  to be  reversible. Competi-
tion  for DNA-binding  sites  has been described, where 
HIF-1α  binds  sequences directly  overlapping E boxes, 
blocking c-Myc DNA binding and inhibiting α-fetoprotein 
expression in HepG2 cells (Mazure et al., 2002).
Direct  HIF-α  effects  on  c-Myc  transcriptional  activ-
ity may be attenuated in c-Myc-overexpressing cells by 




c-Myc  is  dysregulated,  but  not  highly  overexpressed. 
The effects of HIF on c-Myc have not been described 




Mxi  induction  causing  decreased  levels  of  c-Myc  tar-
gets ODC, CAD,  and peroxisome proliferator-activated 






mation  (Harper  et  al.,  1996).  Intriguingly,  Mxi  acts  on 
only a subset of c-Myc targets, repressing ODC but not the DNA synthesis enzyme Ribose-5-Phosphate  Isom-
erase  (O’Hagan et  al.,  2000). As HIF-1α  directly  inhib-
its c-Myc transcriptional effects, hypoxic Mxi induction 











Models for HIF/Myc Interplay in Tumors




exhibit  constitutively  high  c-Myc  target  gene  expres-
sion, HIF-1α should transiently divert substrates away 
from  anabolic  synthesis  and  inhibit  c-Myc  transcrip-
tional  activity  only  when  O2  levels  are  dangerously 
low  (<1%  O2).  However,  any  appreciable  effect  on 
mitochondrial  mass  or  metabolic  enzyme  expression 
following  short  periods  of  HIF  activation  is  unlikely. 
Similarly,  hypoxia  disrupts  the  eIF-4F  complex,  tem-
porarily  inhibiting  translation  without  dismantling  the Cancer Cell 12, August 2007 ©2007 Elsevier Inc.  111
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Minireviewtranslational  machinery  components.  When  O2  levels 
return to normal, a tumor can then return to rapid pro-
liferation  under  the  influence  of  c-Myc.  HIF-2α  likely 




is  also  associated  with  worse  prognosis  than  HIF-1α 
expression  in  some  tumors  (e.g.,  non-small-cell  lung 
and  head  and  neck  cancer;  Semenza,  2003).  HIF-2α 






more  complex,  partly  because  some  renal  tumors 
express  different  HIF-α  subunits  (Mandriota  et  al., 
2002).  Those  expressing  HIF-2α  exclusively  exhibit 
enhanced  c-Myc-dependent  proliferation,  while  HIF 




translation  (through  REDD1)  and  mitochondrial  mass 
(via Mxi). In both cases, lipid accumulation is promoted, 
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